Core Viewpoint - Shanghai RunDa Medical Technology Co., Ltd. has triggered the redemption clause for its convertible bonds due to stock price performance but has decided not to exercise this right at this time [1] Group 1: Redemption Clause Trigger - The company's stock has met the condition of closing prices being no less than 130% of the current conversion price for at least 15 out of 30 consecutive trading days from August 25 to September 17, 2025 [1] - The board of directors has decided not to exercise the early redemption right on September 17, 2025, and will also refrain from exercising this right for the next three months, from September 18 to December 17, 2025 [1] Group 2: Future Considerations - After December 17, 2025, if the redemption conditions are met again, the board will make a further decision regarding the redemption [1] - The relevant parties have not held the convertible bonds before the redemption conditions were met and have no plans to reduce their holdings in the next six months [1] Group 3: Convertible Bond Details - The "RunDa Convertible Bonds" were listed on July 13, 2020, with an initial conversion price of 13.36 yuan per share, which has been adjusted to 12.97 yuan per share [1]

关于上海润达医疗科技股份有限公司 2025年第一次临时股东大会的 上海泽昌律师事务所 上海市浦东新区向城路 288 号国华人寿金融大厦 1107A 室 电话：021-61913137 传真：021-61913139 邮编：200122 二〇二五年九月 上海泽昌律师事务所 法律意见书 上海泽昌律师事务所 关于上海润达医疗科技股份有限公司 法律意见书 2025 年第一次临时股东大会的 法律意见书 泽昌证字 2025-01-12-02 致：上海润达医疗科技股份有限公司 上海泽昌律师事务所（以下简称"本所"）接受上海润达医疗科技股份有限公 司（以下简称"公司"）委托，就公司召开 2025 年第一次临时股东大会（以下 简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简 称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）中国 证券监督管理委员会发布的《上市公司股东会规则》（以下简称"《股东会规则》"） 等法律、法规、规章和其他规范性文件以及《上海润达医疗科技股份有限公司章 程》（以下简称"《公司章程》"）的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务 ...

上海润达医疗科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-050 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | | 1、出席会议的股东和代理人人数 | 585 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 203,649,582 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 33.7354 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，采用现场及通讯记名投票表决和网络投票 表决相结合的方式召开。公司董事长张诚栩先生主持会议 ...

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Group 1 - The company Shanghai RunDa Medical Technology Co., Ltd. has issued convertible bonds known as "RunDa Convertible Bonds" with a total issuance amount of 55 million yuan, which were approved by the China Securities Regulatory Commission [2][3] - The bonds have a maturity period of 6 years and a tiered interest rate structure, starting from 0.3% in the first year and reaching 2.0% in the sixth year [2][3] - The initial conversion price for the bonds was set at 13.36 yuan per share, which has been adjusted multiple times due to profit distributions, currently standing at 13.10 yuan per share [3] Group 2 - The company has established conditional redemption terms for the convertible bonds, allowing for redemption if the stock price remains above 130% of the conversion price for at least 15 out of 30 trading days [4][6] - As of the latest update, the company's stock has already met the condition for 10 trading days, and if it continues to meet the criteria, the company may decide to redeem the bonds [6][4] - The redemption will be executed at the face value plus accrued interest, as per the terms outlined in the bond issuance prospectus [4][5]

Core Viewpoint - The case of Dong Hua, former head of the laboratory department at Gong'an County People's Hospital, highlights corruption in the medical procurement sector, involving two listed companies, Dahua Gene and Run Da Medical, with significant financial implications for the industry [1][2][3]. Company Summaries - Dong Hua was sentenced to 10 years in prison for bribery and 6 months for money laundering, with a total fine of 1 million yuan, after accepting bribes totaling 6.5 million yuan from five entities and individuals from 2010 to 2023 [1][2]. - Dahua Gene's regional director, Qiao Peng, and Hu Yingguo, the actual shareholder of Wuhan Run Da, were identified as bribers in the case, with Dahua Gene benefiting from sales of medical equipment and supplies to the hospital [1][3]. - Dahua Gene reported a revenue of 339 million yuan in the first half of 2025, a decrease of 15.44% year-on-year, with a net loss of 182 million yuan, although this represented a significant reduction in losses compared to the previous year [4][5]. - Run Da Medical's first half of 2025 revenue was 3.47 billion yuan, down 16.08% year-on-year, with a net loss of 121 million yuan, reflecting a 232.14% decline compared to the previous year [5]. - Both companies are facing challenges due to intensified competition in the in vitro diagnostics (IVD) industry, driven by ongoing centralized procurement policies and price adjustments, leading to declining demand and prices for testing services [4][5].

| | | 上海润达医疗科技股份有限公司 关于"润达转债"预计满足赎回条件的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、可转债发行上市概况 （一）经中国证券监督管理委员会证监许可[2020]586 号文核准，上海润达 医疗科技股份有限公司（以下简称"公司"）于 2020 年 6 月 17 日公开发行了 5,500,000 张（550,000 手）可转换公司债券，每张面值 100 元，发行总额 55,000 万元，发行期限 6 年，票面利率分别为：第一年 0.3%、第二年 0.6%、第三年 1.0%、 第四年 1.5%、第五年 1.8%、第六年 2.0%。 （二）经上海证券交易所"[2020]185 号"自律监管决定书同意，公司 55,000 万元可转换公司债券于 2020 年 7 月 13 日起在上海证券交易所上市交易，债券简 称"润达转债"，债券代码"113588"。 （三）根据有关规定和《上海润达医疗科技股份有限公司公开发行可转换公 司债券募集说明书》（以下简称"《募集说明书》"）的约定，公司本次发行的 ...

Investment Rating - The investment rating for the company is maintained as "Buy" [5] Core Views - The company's traditional business is under pressure, while its AI medical business is accelerating its implementation [2] - In the first half of 2025, the company reported a revenue of 3.47 billion yuan, a year-on-year decrease of 16.08%, and a net profit attributable to shareholders of -121 million yuan, a year-on-year decrease of 232.14% [2][3] - The second quarter of 2025 showed a revenue of 1.81 billion yuan, a year-on-year decrease of 12.32%, with a net profit of -51 million yuan, a year-on-year decrease of 174.81% [2][3] Business Performance Summary - The second quarter losses narrowed compared to the first quarter, indicating a trend of gradual improvement [3] - The overall performance is under pressure mainly due to the IVD industry being affected by centralized procurement and price reductions, leading to a decline in product prices [3] - The revenue from the centralized and regional testing business in the first half of 2025 was 932 million yuan, down 24.59% year-on-year, while the industrial segment generated 210 million yuan, down 7.18% year-on-year [3] - The third-party laboratory business reported a revenue of 60.19 million yuan, down 18.80% year-on-year, primarily due to price reductions in certain testing projects [3] AI Medical Business Development - The company is deepening its AI strategy, with medical information business revenue reaching 94 million yuan in the first half of 2025, a year-on-year increase of 40.73% [4] - The AI layout covers B, C, and G ends, creating a closed-loop ecosystem from pre-diagnosis to post-diagnosis [4] - The company has provided AI solutions to over 100 hospitals, including Huaxi Hospital and Qilu Hospital, enhancing specialized diagnostic capabilities [4] Investment Recommendations - The company is expected to achieve revenues of 8.08 billion yuan, 8.70 billion yuan, and 9.46 billion yuan from 2025 to 2027, with year-on-year growth rates of -2.7%, 7.6%, and 8.7% respectively [5] - The net profit attributable to shareholders is projected to be 199 million yuan, 238 million yuan, and 275 million yuan for the same period, with year-on-year growth rates of 260.0%, 19.8%, and 15.2% respectively [5] - The corresponding EPS is expected to be 0.33 yuan, 0.40 yuan, and 0.46 yuan, with PE multiples of 52, 43, and 37 times [5]

Core Viewpoint - The AI Fund Yinhua Medical Health Mixed A (018364) reported a profit of 1.0427 million yuan for the first half of 2025, with a net value growth rate of 2.57% and a fund size of 35.6523 million yuan as of the end of June 2025 [2][30]. Fund Performance - As of September 5, 2025, the fund's one-year cumulative net value growth rate was 17.70%, ranking 130 out of 136 comparable funds [5]. - The fund's net value growth rate over the past three months was 17.21%, ranking 101 out of 138 comparable funds, while the six-month growth rate was 5.29%, ranking 135 out of 138 [5]. Investment Strategy - The fund manager expressed an optimistic outlook for the second half of the year, citing reduced risks in the pharmaceutical industry's profitability and a turning point in the sector's performance due to policy improvements and the expansion of commercial insurance [2]. - The fund's investment focus is primarily on AI pharmaceuticals and AI healthcare, with a belief that the cost reduction and efficiency improvements brought by AI in the pharmaceutical industry are not yet fully recognized [2]. Valuation Metrics - As of June 30, 2025, the fund's weighted price-to-earnings (P/E) ratio was approximately -279.03, significantly lower than the industry average of 120.96 [9]. - The weighted price-to-book (P/B) ratio was about 2.76, compared to the industry average of 4.07, and the weighted price-to-sales (P/S) ratio was approximately 3.61, against an average of 6.52 [9]. Growth Metrics - For the first half of 2025, the fund's weighted revenue growth rate was -0.03%, and the weighted net profit growth rate was -0.55%, indicating a decline in growth [14]. Fund Composition - As of June 30, 2025, the fund had 848 holders, with a total of 40.4478 million shares held. Institutional investors accounted for 52.59% of the holdings, while individual investors made up 47.41% [33]. - The fund's top ten holdings included companies such as Jingtai Holdings, Yimai Tong, and JD Health, reflecting a focus on key players in the healthcare sector [39].

Market Performance - The pharmaceutical commercial sector increased by 0.4% compared to the previous trading day, with Baiyang Pharmaceutical leading the gains [1] - On the same day, the Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Individual Stock Performance - Baiyang Pharmaceutical (301015) closed at 27.16, with a rise of 4.14% and a trading volume of 108,200 shares, amounting to a transaction value of 287 million yuan [1] - Other notable performers included Guofang Co. (600538) with a 2.14% increase, and Runda Medical (603108) with a 1.79% increase [1] - Conversely, Selin Medical (603716) saw a decline of 1.21%, with a trading volume of 289,200 shares and a transaction value of 809 million yuan [2] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 16.35 million yuan from institutional investors, while retail investors saw a net inflow of 11.97 million yuan [2] - The data indicates that retail investors are showing interest in the sector despite the overall net outflow from institutional investors [2] Detailed Capital Flow for Selected Stocks - Runda Medical (603108) had a net inflow of 16.55 million yuan from institutional investors, while it faced a net outflow of 10.39 million yuan from retail investors [3] - China Medical (600056) also saw significant institutional inflows of 15.68 million yuan, but retail investors withdrew 5.26 million yuan [3] - Baiyang Pharmaceutical (301015) had a net inflow of 12.71 million yuan from institutional investors, with retail investors withdrawing 11.58 million yuan [3]